Sculptra Treatment

This article will spell out what Sculptra treatment is and just how it functions to enhance your appearance.

Poly-1-lactic acid (PLLA), a.k.a. Sculptra, was approved by FDA in 2004 for the treatment of AIDS-mediated facial lipoatrophy. It’s inserted by injection into the subcutaneous tissue and triggers skin cell replication. A number of injections are necessary, but the aesthetic results for sunken cheek have been formidable. In the Europe-based studies, the effect persisted for 18-24 months. Aesthetic use of this substance is considered off-label, but has been utilized for pan facial augmentation. It’s very important to insert this product into the right level. Injection into the dermis could increase the chance of granulomas.

Here’s how PLLA works.

Facial fat atrophy may cause significant alteration in appearances and may be due to hereditary syndromes, disease or aging. In natural ageing, it happens in the form of loss of elasticity, degradation of collagen and reabsorption of bone. This sinking due to volume loss results in further skin redundancy.

A few degrees of lipoatrophy based upon anatomic considerations have been detailed. Trying to rectify by tightening without addressing volume replacement causes a skeletonized look. Volume replenishment has been attempted by various naturally-found (fat, collagen, hyaluronic acid) and man-made (acrylates, silicone and other polymers) fillers, both biodegradable (that is the body can break them down) and imperishable. Poly-L-lactic acid (PLLA), marketed in US and Europe as Sculptra, is a new type of fibroblastic fillers whose ‘volumizing effect’ is dependant on host response.

Injectable Poly-L-lactic acid, also known as Sculptra, is a biocompatible, reabsorbable material that kickstarts an intended foreign body inflammatory response, regeneration of skin cells and a slow metabolic degradation of the polymer microspheres. Histological and clinical data allude to long-lasting effects, that may last for longer than 2 years. Currently, Sculptra is FDA-approved solely for the indication of AIDS-mediated lipoatrophy, and esthetic usage are ‘off-label’, although randomised clinical studies for cosmetic usage are currently almost complete. Quite a few documentations summarise the biological effects and treatment of lipoatrophy with Sculptra.